Non-invasive Diagnostic Model of Liver Fibrosis Associated With NAFLD and Prediction of Prognosis
NCT ID: NCT03842748
Last Updated: 2019-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
300 participants
OBSERVATIONAL
2018-01-01
2021-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Application of Non-invasive Assessment for Staging Liver Steatosis and Liver Fibrosis
NCT03386890
68Ga-FAPI PET/CT in Liver Fibrosis Patients
NCT04533828
Dynamic Changes and Risk Factors of Fibrosis and Steatosis Progression in Nonalcoholic Fatty Liver Disease
NCT03635541
Accuracy of Imaging Techniques in Diagnosing Steatohepatitis and Fibrosis in NAFLD Patients
NCT04785937
18F-FAPI PET in the Diagnosis of Liver Fibrosis
NCT05262647
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Retrospective study group
200 patients with non-alcoholic fatty liver disease, fatty liver hepatitis, and fibrosis have been identified for pathological diagnosis of liver histology and without other liver diseases. Before liver biopsy were performed, liver function, coagulation function, renal function, blood glucose, blood lipids, liver elasticity measurement, imaging indicators and demographic data were detected and recorded. To evaluate diagnostic ability of current non-invasive diagnostic model of NAFLD fibrosis and adaptability of model indicators to diagnosis of these patients, and correct the indicators including discarding unsuitable and incorporating new indicators and adjusting the diagnostic score. Establish a non-invasive diagnostic model for liver fibrosis in Beijing based on NAFLD.
No interventions assigned to this group
Prospective observational study group
100 patients without other liver diseases and ultrasound-tested fatty liver were enrolled, and histopathological diagnosis of liver were included , and liver function, coagulation function, renal function, blood glucose, and non-invasive model analysis, blood lipids, liver elasticity measurements and imaging indicators were examined and demographic data were collected. Adjusted the index of non-invasive diagnostic model to further revise and improve the diagnostic efficacy of diagnostic model. Long-term follow-up observations were performed in the prospective observation cohort. To explore the correlation and predictive ability of noninvasive diagnostic models for long-term outcomes of disease. Finally, a model for predicting the outcome of progression of liver fibrosis in NAFLD was established.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Age between 18 and over 75;
3. patient were never treated with no hormones and / or immunosuppressants and other liver protection drugs.
Exclusion Criteria
2. autoimmune liver disease;
3. HIV infection;
4. long-term alcohol abuse and / or other liver damage drugs;
5. mental illness;
6. Evidence of liver tumors (liver cancer or AFP \> 100 ng/ml);
7. decompensated cirrhosis;
8. Serious diseases such as heart, brain, lung, kidney, etc. can not participate in long-term follow-up.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Beijing Municipal Administration of Hospitals
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Minghui Li
Head of Liver Diseases Center
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Minghui Li, master
Role: PRINCIPAL_INVESTIGATOR
Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
XXZ0302
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.